While the positive effect of this expansion on Biota may be significant and GSK have confirmed it has contracts to supply Relenza to over 60 countries, the announcement is focussed on increased manufacturing capacity for Relenza, not orders or sales. GSK has stated that additional regulatory approvals will be required and that the capacity increases are planned for the end of calendar 2009. The expansion of Relenza capacity and any increase in resultant royalty payments, will not effect Biota’s cash position until June 2010, at the earliest.
this is from the latest quartly report..it make it hard to estimate the next royalty payment....GSK seems to be giving conflicting statements...so it might take longer than we would want to finalise the orders and pay the bigger royalities we are hoping for the outlook for BTA is still very positive ..any news on Lani would be a big bost to the share price
BTA Price at posting:
$2.93 Sentiment: Hold Disclosure: Held
